Monoclonal antibody holds promise of reducing learning, memory problems in schizophrenia

Chronic learning and memory problems that plague patients with schizophrenia may have a worthy foe in a monoclonal antibody that also holds promise in the fight against cancer and is already used to treat a rare disorder similar to lymphoma, researchers say.

Siltuximab directly targets interleukin 6, or IL-6, a protein and cytokine that is a key regulator of inflammation, which is often elevated in patients with schizophrenia, said Dr. Brian J. Miller, psychiatrist and schizophrenia expert in the Department of Psychiatry and Health Behavior at the Medical College of Georgia at Augusta University.

Read the full story here:

http://nbc26.tv/2016/01/26/monoclonal-antibody-holds-promise-of-reducing-learning-memory-problems-in-schizophrenia/

2 Likes